重组人血管内皮抑制素结合放化疗对鼻咽癌临床疗效、预后及血清血管内皮生长因子的影响

发布时间：2018-02-23 02:26

本文关键词： 重组人血管内皮抑制素鼻咽癌血管内皮生长因子　出处：《中国老年学杂志》2017年17期 　论文类型：期刊论文

【摘要】：目的探讨重组人血管内皮抑制素结合放化疗对鼻咽癌患者临床疗效、预后及血清血管内皮生长因子(VEGF)水平的影响。方法90例老年鼻咽癌患者随机分为观察组和对照组。对照组采用放化疗方案进行治疗,观察组在对照组基础上采用重组人血管内皮抑制素进行治疗。治疗前及治疗后检测血清中VEGF水平,记录患者治疗期间不良反应发生情况,结束治疗4 w后采用鼻咽部MRI、鼻咽镜、胸部CT等手段进行疗效评价;对患者进行为期3年的随访,统计患者生存率(OS)及无进展生存时间(PFS)。结果观察组治疗有效率优于对照组(χ2=5.700,P0.05);治疗后两组血清VEGF水平显著低于治疗前,且观察组显著低于对照组(均P0.05);观察组OS及PFS均显著优于对照组(P0.05);两组不良反应发生率差异无统计学意义(P0.05)。结论重组人血管内皮抑制素结合放化疗手段可有效改善鼻咽癌患者临床疗效,提高患者预后并可有效改善血清中VEGF水平。
[Abstract]:Objective to investigate the clinical effect of recombinant human vascular endotheliostatin combined with radiotherapy and chemotherapy on patients with nasopharyngeal carcinoma (NPC). Methods 90 elderly patients with nasopharyngeal carcinoma were randomly divided into observation group and control group. The patients in the observation group were treated with recombinant human vascular endotheliostatin before and after treatment. The adverse reactions of the patients were recorded before and after treatment. After 4 weeks of treatment, nasopharyngeal MRI and nasopharyngoscope were used. The curative effect was evaluated by chest CT, the survival rate and survival time of the patients were calculated after 3 years follow-up. Results the effective rate of treatment in the observation group was better than that in the control group (蠂 2 5.700 P 0.05), the serum VEGF level of the two groups was significantly lower than that of the control group after treatment. The observation group was significantly lower than the control group (all P 0.05), the observation group OS and PFS were significantly better than the control group (P 0.05), there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Recombinant human vascular endothelial inhibitor combined with radiotherapy and chemotherapy can be effectively modified. Clinical efficacy of patients with nasopharyngeal carcinoma, It can improve the prognosis and improve the serum VEGF level.
【作者单位】：青海省红十字医院肿瘤内科;青海省红十字医院放疗科;
【分类号】：R739.63

【相似文献】